Table 1.
Patient demographics
| Characteristic | Finding | Range (min-max) |
|---|---|---|
| Age (years) | 57 +/− 15 | 20–83 |
| Female gender, n (%) | 40 (80) | |
| Height (m) | 1.63 (1.56–1.73) | 1.46–1.95 |
| Weight (kg) | 71 +/− 16 | 40–105 |
| BSA (m2) | 1.8 +/− 0.2 | 1.4–2.4 |
| 6MWD (metres) | 333 (150–440) | 0–582 |
| NT-proBNP (ng/L) | 320 (110–841) | 50–52,746 |
| WHO FC, n (%) | ||
| 1 | 2 (4) | |
| 2 | 12 (24) | |
| 3 | 32 (64) | |
| 4 | 4 (8) | |
| PAH, n (%) | 39 (78) | |
| Group 1 | 33 (66) | |
| - Idiopathic | 8 | |
| - CTD | 23 | |
| - PVOD | 1 | |
| - Portopulmonary | 1 | |
| Group 2 | 2 (4) | |
| Group 3 | 2 (4) | |
| Group 4 | 1 (2) | |
| Group 5 | 1 (2) | |
| PAH therapy, n (%) | ||
| - Phosphodiesterase type 5 inhibitor | 24 (48) | |
| - Endothelin receptor antagonist | 23 (46) | |
| - Intravenous Epoprostenol | 2 (4) | |
All normally distributed data are presented as mean ± standard deviation, non-parametric data are presented as median (Q1-Q3) and proportions as n (%)
BSA Body surface area, CTD Connective tissue disease, NT-proBNP N-terminal pro-brain natriuretic peptide, PAH Pulmonary artery hypertension, PVOD Pulmonary veno-occlusive disease, WHO FC World Health Organisation Functional Class, 6MWD 6-min walk distance